Cited by 118Alzheimer's disease research and treatmentsMass Spectrometry Techniques and ApplicationsAdvanced Proteomics Techniques and Applications

Pulsed hydrogen–deuterium exchange mass spectrometry probes conformational changes in amyloid beta (Aβ) peptide aggregation

Open access
Zhang, Ying, Rempel, Don L., Zhang, Jun, Sharma, Anuj K., Mirica, Liviu M., Gross, Michael L.·2013·Proceedings of the National Academy of Sciences

Abstract

Probing the conformational changes of amyloid beta (Aβ) peptide aggregation is challenging owing to the vast heterogeneity of the resulting soluble aggregates. To investigate the formation of these aggregates in solution, we designed an MS-based biophysical approach and applied it to the formation of soluble aggregates of the Aβ42 peptide, the proposed causative agent in Alzheimer's disease. The approach incorporates pulsed hydrogen-deuterium exchange coupled with MS analysis. The combined approach provides evidence for a self-catalyzed aggregation with a lag phase, as observed previously by fluorescence methods. Unlike those approaches, pulsed hydrogen-deuterium exchange does not require modified Aβ42 (e.g., labeling with a fluorophore). Furthermore, the approach reveals that the center region of Aβ42 is first to aggregate, followed by the C and N termini. We also found that the lag phase in the aggregation of soluble species is affected by temperature and Cu(2+) ions. This MS approach has sufficient structural resolution to allow interrogation of Aβ aggregation in physiologically relevant environments. This platform should be generally useful for investigating the aggregation of other amyloid-forming proteins and neurotoxic soluble peptide aggregates.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1309175110

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 3

  1. Kim J, et al. (2007) Abeta40 inhibits amyloid deposition in vivo. J Neurosci 27(3):627-633.
  2. Sharma AK, et al. (2012) Bifunctional compounds for controlling metal-mediated aggregation of the aβ42 peptide. J Am Chem Soc 134(15):6625-6636.
  3. Yan Y, Wang C (2007) Abeta40 protects non-toxic Abeta42 monomer from aggre- gation. J Mol Biol 369(4):909-916.

Cited by

Sorted by citations

Authors
Zhang, Y., Rempel, D. L., Zhang, J., Sharma, A. K., Mirica, L. M., & Gross, M. L.
Affiliations
California Institute of Technology (US)
Venue
Proceedings of the National Academy of Sciences
Published
2013-08-19
Volume
110
Issue
36
Pages
14604-14609
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2165610594
Cited by
118
References
71
Citations by year
2026: 1 · 2025: 5 · 2024: 4 · 2023: 12 · 2022: 10 · 2021: 7 · 2020: 14 · 2019: 9 · 2018: 12 · 2017: 7 · 2016: 8 · 2015: 12 · 2014: 13 · 2013: 4
FWCI
8.59
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Association (AG05681, NIRP-12-259199, 12-259199)
  • Oak Ridge Associated Universities
  • National Institutes of Health (GM103422, AG05681)
  • Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St. Louis (P50 AG0568 1)
  • National Institute on Aging (P 50 AG05681, P50AG005681)
  • National Institute of General Medical Sciences (GM103422, P41GM103422)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
Keywords
amyloid-beta, amyloid-beta 42, peptide aggregation, hydrogen-deuterium exchange, conformational change, lag phase, Alzheimer's disease, copper ions, temperature effects
MeSH terms
Alzheimer Disease, Amyloid, Copper, Deuterium, Humans, Hydrogen, Peptide Fragments, Protein Conformation, Mass Spectrometry, Temperature, Blotting, Western, Amyloid beta-Peptides, Deuterium Exchange Measurement, Microscopy, Electron, Transmission

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review